Cancer drug spending hits $100M in 2014; ArQule gets into PD-1/PD-L1;

@FierceBiotech: ICYMI yesterday: Bayer fronting $155M for a promising anticoagulant from Isis Pharma. Report | Follow @FierceBiotech

@JohnCFierce: The drumbeat of bad news at $GSK should lead to a change of CEOs. Breaking up the co. will be the focus as well. More from Bloomberg | Follow @JohnCFierce

> Global spending on cancer drugs soared to $100 billion in 2014, according to IMS Health, a 10.3% jump over the prior year. News

> ArQule ($ARQL) inked a deal with Beryllium Discovery to collaborate on small-molecule therapies targeting PD-1 and PD-L1, proteins that play a role in the immune system's ability to fight cancer. More

Medical Device News

@FierceMedDev: Myriad Genetics stumbles as rivals flood BRCA market. FierceDiagnostics story | Follow @FierceMedDev

@EmilyWFierce: Scientists harness new technology for artificial knee implants. Report | Follow @EmilyWFierce

> Open-source software released to connect Apple ResearchKit to the cloud for use in clinical trials. News

> Researchers question safety of off-label device use in atrial fibrillation, call for 510(k) review process. Report

Pharma News

@FiercePharma: India eases path for small companies to bid in medical product tenders. FiercePharmaAsia article | Follow @FiercePharma

@EricPFierce: ICYMI: Novo putting $225M into new plant in Denmark for hemophilia treatments. Report | Follow @EricPFierce

@CarlyHFierce: Big new launches rocket cancer drug spending to $100B: IMS report. More | Follow @CarlyHFierce

> Drugmakers to Congress: You want patent reforms? Stop pharma challenger Bass. Article

> Momenta/Sandoz Copaxone generic may be the only one around for a while, exec says. Story

Pharma Manufacturing News

> Zoetis to whack 10 plants as part of cost-cutting scheme. News

> U.K. regulators find issues with Indian-owned API distributor Relonchem. More

> WuXi starts work in China on yet another cell-line manufacturing facility. Article

> Recro Pharma and Alkermes close deal on DEA-approved plant in Georgia. Story

> Novo building $225M plant for hemophilia treatments. Report

Pharma Asia News

> China's SAIC denies probe as reports proliferate on alleged devices crackdown. Article

> India eases path for small companies to bid in medical product tenders. Story

> China plans first-ever rules on animal testing in medical research by year end. More

> Otsuka device unit works with UniCare on urinary bladder products. Report

> Japan to adopt CDISC clinical data standards from October 2016. Item

Drug Delivery News

> NIH says viral vector for delivering gene therapy to treat blindness shows promise, Wall Street less sure. More

> UNC scientists bypass blood-brain barrier with exosomes to treat Parkinson's. Report

> Northwestern team puts spherical RNA in common skin moisturizer to speed up wound healing. Story

> Medicines Co. gets FDA approval of first patient-controlled patch for postoperative pain. Item

> Deerfield Management buys 8% stake in manufacturer of custom hydrogels and wound dressings. Article

Suggested Articles

Tango Therapeutics is ditching its digs in Kendall Square to move into a new building in Boston’s Fenway neighborhood. Third Rock is coming, too.

UPenn scientists found blocking the Wnt/beta-catenin pathway in endothelial cells made chemotherapy more effective in mouse models of glioblastoma.

The Japanese drugmaker pulled the trigger on the deal after getting a look at phase 1 data on the glutenase TAK-062.